Skip To Main Content
GR Burmester on Muck Rack

GR Burmester

As seen in: ScienceDirect
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with GR

Contact GR, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study

|
By P Emery, VP Bykerk, GR Burmester, DE Furst
| ScienceDirect Verified
Discussion This international, post-marketing, 10-year observational safety study found no evidence of a significantly increased risk of overall malignancies, breast cancer, or lung cancer for over 5000 patients with RA undergoing treatment with abatacept in routine clinical practice compared with those treated with csDMARDs or other b/tsDMARDs. For patients with lymphoma, evidence of a statistically significantly increased risk was noted with abatacept compared with other b/tsDMARDs in one...
Open in Who Shared Issue with article?
See all 1 articles